Cancer nanomedicines were initially envisioned as magic bullets, travelling through the
circulation to target tumours while sparing healthy tissues the toxicity of classic …

Current cancer nanomedicines can only mitigate adverse effects but fail to enhance
therapeutic efficacies of anticancer drugs. Rational design of next‐generation cancer …

Doxorubicin (DOX) is a potent anti-cancer agent that has garnered great interest in research
due to its high efficacy despite dose-limiting toxicities. Several strategies have been …

Orally administrable anticancer nanomedicines are highly desirable due to their easy and
repeatable administration, but are not yet feasible because the current nanomedicine cannot …

siRNA is a promising therapeutic solution to address gene overexpression or mutations as a
post-transcriptional gene regulation process for several pathological conditions such as viral …

In recent years, the nanotechnology has offered researchers the opportunity to solve the
problems caused by the vehicle of the standard and first formulation of paclitaxel (Taxol®) …

Recent progress in RNA biology has broadened the scope of therapeutic targets of RNA
drugs for cancer therapy. However, RNA drugs, typically small interfering RNAs (siRNAs) …

Nanomedicines, while having been approved for cancer therapy, present many challenges
such as low stability, rapid clearance, and nonspecificity leading to off-target toxicity …

To efficiently deliver anti-cancer drug to tumor site and reduce its toxic side effects on normal
tissues, a polyethylene glycol (PEG) shielding and tumor microenvironment triggering …

As the physicochemical properties of drug delivery systems are governed not only by the
material properties which they are compose of but by their size that they conform, it is crucial …